Key facts
- Noveome Biotherapeutics’s last known valuation is $200.0M (Apr 2019).
- It has raised $78.7M across 4 recorded rounds; the latest was Early Stage VC ($36.2M) in Aug 2023.
- Notable investors include UPMC Enterprises, Carnegie Mellon University, Commonwealth of Pennsylvania, MAK Capital, University of Pittsburgh Endowment — 10 tracked in total.
- Noveome Biotherapeutics has filed 6 Form Ds with the SEC since 2016, most recently Aug 2024 ($36.2M sold to 66 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Noveome Biotherapeutics
Funding rounds
4 roundsAbout Noveome Biotherapeutics
Developer of novel biotherapeutic products designed to treat inflamed or damaged tissues. The company's products contain numerous biologic components at physiologic concentrations which function in combination and synergistically to yield anti-inflammatory, neuroprotective, anti-apoptotic and vascular integrity preservative activities, enabling healthcare providers to provide treatment of complex diseases.
- Sector
- Healthcare
- HQ
- Pittsburgh, PA, United States
- Founded
- 2000
- Employees
- 26
- Website
- noveome.com/
- Ownership
- Privately Held (backing)
Noveome Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Noveome Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Noveome Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.